Education
About Us
Working with TipRanks
Follow Us
Neovacs SA (FR:ALNEV)
:ALNEV
ALNEV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.04 - €6,004.58
Previous CloseN/A
Volume950.00
Average Volume (3M)254.84K
Market Cap
€12.11K
Enterprise Value€413.65K
Total Cash (Recent Filing)€1.42M
Total Debt (Recent Filing)€231.05K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Oct 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-160192.50
Shares Outstanding269,590
10 Day Avg. Volume453,767
30 Day Avg. Volume254,842
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.59
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Neovacs SA News
PremiumCompany Announcements
Neovacs Optimizes Financing Strategy with Trust Agreement Amendment
PremiumCompany Announcements
Néovacs Raises €0.25 Million for Allergy Research Amid Dilution Concerns
PremiumCompany Announcements
Néovacs Reports Share Capital Structure Amid Dilutive Financing Concerns
PremiumCompany Announcements
Néovacs Seeks Partners for mRNA Asthma Program Valued at €98 Million
PremiumCompany Announcements
Neovacs Embraces mRNA and Strategic PartnershipsPremiumCompany Announcements
Neovacs SA Initiates Share Consolidation
PremiumCompany Announcements
Neovacs SA Announces Capital Reduction and Share Dilution---
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.04 and its highest was €6004.58 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €12.11K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 23, 2025 which is in 201 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Oct 31, 2024. The company reported -€33192.5 earnings per share for the quarter, missing the consensus estimate of N/A by -€33192.5.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 269,590 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€33192.5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
---
Company Description
Neovacs SA
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
---
Technical Analysis
---